Your Gene ATG GGT. pd1118 EF1a-ORF, Lenti-ElecD 7803 bp

Similar documents
~Lentivirus production~

Certificate of Analysis

Certificate of Analysis

DNA context and promoter activity affect gene expression in lentiviral vectors

VIROLOGY. Engineering Viral Genomes: Retrovirus Vectors

Pre-made Lentiviral Particles for Fluorescent Proteins

Fayth K. Yoshimura, Ph.D. September 7, of 7 RETROVIRUSES. 2. HTLV-II causes hairy T-cell leukemia

Recombinant Protein Expression Retroviral system

Constitutive Reporter Lentiviral Vectors Expressing Fluorescent Proteins

Jumpstart your research with ViraPower Lentiviral Expression Systems

Lecture 2: Virology. I. Background

Auxin-Inducible Degron (AID) System Total Set

Choosing Between Lentivirus and Adeno-associated Virus For DNA Delivery

Retroviruses. ---The name retrovirus comes from the enzyme, reverse transcriptase.

Pre-made Reporter Lentivirus for JAK-STAT Signaling Pathway

Viral Vectors In The Research Laboratory: Just How Safe Are They? Dawn P. Wooley, Ph.D., SM(NRM), RBP, CBSP

Pre-made Reporter Lentivirus for MAPK/ERK Signal Pathway

Trans-Lentiviral TM Packaging System

Introduction retroposon

L I F E S C I E N C E S

7.012 Problem Set 6 Solutions

Pre-made Reporter Lentivirus for NF-κB Signal Pathway

Ready-to-use Lentiviral Particles for intracelular labeling

October 26, Lecture Readings. Vesicular Trafficking, Secretory Pathway, HIV Assembly and Exit from Cell

Name Section Problem Set 6

CRISPRaTest Functional dcas9-activator Assay Kit v1 Last update: 2018/07/04 Cellecta, Inc.

Supplemental Materials and Methods Plasmids and viruses Quantitative Reverse Transcription PCR Generation of molecular standard for quantitative PCR

Pre-made Lentiviral Particles for intracelular labeling: (LocLight TM Living cell imaging lentivirus for sub-cellular localization)

CURRENT DEVELOMENTS AND FUTURE PROSPECTS FOR HIV GENE THERAPY USING INTERFERING RNA-BASED STRATEGIES

Transcription and RNA processing

Supplementary Information. Novel lentiviral vectors with mutated reverse transcriptase for mrna delivery of TALE nucleases

Overview of the Expressway Cell-Free Expression Systems. Expressway Mini Cell-Free Expression System

number Done by Corrected by Doctor Ashraf

Last time we talked about the few steps in viral replication cycle and the un-coating stage:

Section 6. Junaid Malek, M.D.

HIV-1 p24 ELISA Pair Set Cat#: orb54951 (ELISA Manual)

Norgen s HIV proviral DNA PCR Kit was developed and validated to be used with the following PCR instruments: Qiagen Rotor-Gene Q BioRad icycler

Norgen s HIV Proviral DNA PCR Kit was developed and validated to be used with the following PCR instruments: Qiagen Rotor-Gene Q BioRad T1000 Cycler

VIRAL TITER COUNTS. The best methods of measuring infectious lentiviral titer

7.012 Quiz 3 Answers

Hepatitis B Antiviral Drug Development Multi-Marker Screening Assay

Human Immunodeficiency Virus

Graveley Lab shrna knockdown followed by RNA-seq Biosample Preparation and Characterization Document

Protein Synthesis

Chapter 18. Viral Genetics. AP Biology

VIRUSES AND CANCER Michael Lea

Page 32 AP Biology: 2013 Exam Review CONCEPT 6 REGULATION

MedChem 401~ Retroviridae. Retroviridae

Central Dogma. Central Dogma. Translation (mrna -> protein)

7.013 Spring 2005 Problem Set 7

LESSON 4.4 WORKBOOK. How viruses make us sick: Viral Replication

Human Immunodeficiency Virus type 1 (HIV-1) p24 / Capsid Protein p24 ELISA Pair Set

Human Genome: Mapping, Sequencing Techniques, Diseases

Graveley Lab shrna knockdown followed by RNA-seq Biosample Preparation and Characterization Document

AP Biology Reading Guide. Concept 19.1 A virus consists of a nucleic acid surrounded by a protein coat

Transcription and RNA processing

PROTOCOL: OPTIMIZATION OF LENTIVIRAL TRANSDUCTION USING SPINFECTION

NBP Protocol. Orders: Support: Web: NBP

Viruses Tomasz Kordula, Ph.D.

Supplementary Figure 1. Establishment of prostacyclin-secreting hmscs. (a) PCR showed the integration of the COX-1-10aa-PGIS transgene into the

Chapter 19: Viruses. 1. Viral Structure & Reproduction. 2. Bacteriophages. 3. Animal Viruses. 4. Viroids & Prions

Antiviral Drugs Lecture 5

Pre-mRNA has introns The splicing complex recognizes semiconserved sequences

Size nm m m

LentiBoost Lentiviral Transduction Enhancer

Multi-plasmid approach

Viruses. Non-cellular organisms. Premedical - Biology

Chapter 19: Viruses. 1. Viral Structure & Reproduction. What exactly is a Virus? 11/7/ Viral Structure & Reproduction. 2.

Polyomaviridae. Spring

Aperto Cell Lysis and Protein Solubilization Users Manual

Transfection of Sf9 cells with recombinant Bacmid DNA

Module 2 In vivo gene therapy. Lecture 7. In-situ, in-vivo and ex-vivo gene therapy (part I)

OCCUPATIONAL HEALTH CONSIDERATIONS FOR WORK WITH VIRAL VECTORS

Viral Genetics. BIT 220 Chapter 16

Screening for Complex Phenotypes

Data Sheet. Notch Pathway Reporter Kit Catalog # 60509

Reverse Genetics of RNA Viruses

Julianne Edwards. Retroviruses. Spring 2010

Cignal Lenti Reporters

Table of Contents. Product and Service Item of Genemedi Lentivirus...3 Product Character of Genemedi Lentivirus...3

Human Genome Complexity, Viruses & Genetic Variability

A phase I pilot study of safety and feasibility of stem cell therapy for AIDS lymphoma using stem cells treated with a lentivirus vector encoding

AP Biology. Viral diseases Polio. Chapter 18. Smallpox. Influenza: 1918 epidemic. Emerging viruses. A sense of size

Viruses. Picture from:

Feb 11, Gene Therapy. Sam K.P. Kung Immunology Rm 417 Apotex Center

Hepadnaviruses: Variations on the Retrovirus Theme

Biochemistry 2000 Sample Question Transcription, Translation and Lipids. (1) Give brief definitions or unique descriptions of the following terms:

A protocol for enhancement of the AAV-mediated expression of transgenes

Supplementary Figure 1. SC35M polymerase activity in the presence of Bat or SC35M NP encoded from the phw2000 rescue plasmid.

RNA Processing in Eukaryotes *

Overview: Chapter 19 Viruses: A Borrowed Life

Viruses defined acellular organisms genomes nucleic acid replicate inside host cells host metabolic machinery ribosomes

FOXO Reporter Kit PI3K/AKT Pathway Cat. #60643

Supplementary Information. Supplementary Figure 1

DATA SHEET. Provided: 500 µl of 5.6 mm Tris HCl, 4.4 mm Tris base, 0.05% sodium azide 0.1 mm EDTA, 5 mg/liter calf thymus DNA.

TRANSCRIPTION. DNA à mrna

Reverse transcription and integration

Chapter 25. 바이러스 (The Viruses)

Biol115 The Thread of Life"

Transcription:

Mammalian Expression Vectors has mammalian expression vectors suitable for transient or stable expression. These vectors are available with features including various promoters, markers, and fusions. Lentiviral Integration Vectors These vectors are configured to maximize packaging efficiency and expression of the integrated construct. They are available with a choice of mammalian selectable markers and mammalian promoters. Plasmid Map Your Gene ATG GGT EF1_Hs_exon1 P_EF1a-Hs 7000 7500 Intron_EF1a-Hs 1 EES 500 1000 WPRE P_PGK-Mm 6500 6000 pd1118 EF1a-ORF, Lenti-ElecD 7803 bp 1500 2000 LTR_HIV 1 P_Amp M_Blasticidin-r_* 5500 2500 pa_hsv TK 5000 3000 M_Kanamycin-r_* complementary poly purine tract (cppt) 4500 4000 3500 Ori_pUC Rev-responsive element_hiv 1 LTR_RSV Pack_HIV 1 LTR_HIV 1 Name Qty Storage pd1118 10Rx -20 Packaging Protocol 1. Plate 293T cells two days before packaging in a 10cm dish in 10mLs of DMEM supplemented with 10% heat inactivated fetal bovine serum so that cells are 70-90% confluent at time of transfection. 2. Prepare DNA/Lipofectamine Lenti complexes. DNA will include Lentiviral Expression Plasmid and Packaging Plasmids. (At we dilute our plasmid and lipofectmaine in Opti-MEM from LifeTech) 3. Add the DNA/Lipofectamine complex to each 10cm dish and gently swirl to distribute complex. 4. Incubate cells overnight (8-14 hours) in a CO2 incubator at 37 C. 5. Replace culture media (recommended within 14 hours of transfection). 48 hours post transfection harvest lentivirus: Collect culture media in sterile capped tubes. Centrifuge tubes at 500 x g for 10 minutes. After, filter the supernatant through 0.45μm PES (polyethersulfone) low protein-binding filters. (Peak virus production can occur 24-48 hours post transfection. Lentiviral stocks should be made and stored at 80 C. Expect loss of titer with each thaw and freeze cycle.)

Transduction Protocol 1. Plate cells to be 70-80% confluent at time of infection 24 hours prior to infection. 2. Dilute virus suspension in complete media with polybrene at a final concentration of 5-8μg/ml. 3. Remove the old culture medium and replace with diluted viral supernatant. 4. Incubate overnight. 5. Replace old medium with fresh complete medium. 6. Continue incubating for 48 hours in cell specific medium. 7. Analyze cells. (To elect stable cells, replace old medium with fresh complete growth medium containing appropriate selection drug every 72 hours until drug-resistant colonies become visible (generally 7-14 days post selection). Bacterial Propagation E. coli lines transformed with the Lentiviral Vector should be grown at 30 C or lower to maintain plasmid stability. Mammalian Expression Vector Controls 's mammalian expression vectors are available with Protein Paintbox genes to serve as controls. In addition, any mammalian-optimized Paintbox Protein gene in an Electra MOTHER vector can be cloned into any Electra DAUGHTER vector.

Electra Cloning System Electra is a simple one-tube universal cloning process that can be performed in a 5 minute bench-top reaction with the fidelity of a restrictionbased cloning system. A gene from one MOTHER vector is compatible with all DAUGHTER vectors, allowing rapid testing of many different sequence contexts simultaneously. Reagents The Electra Reagents kit contains all necessary components to facilitate cloning a gene from a MOTHER into a DAUGHTER vector. The Electra reaction can also be used to clone a PCR product into either a MOTHER or a DAUGHTER vector. Electra Buffer Mix is supplied at 10X final concentration (use 2 µl in a 20 µl reaction) Electra Enzyme Mix is supplied at 20X final concentration (use 1 µl in a 20 µl reaction) Cloning Protocol Component Volume (µl) MOTHER DNA / Positive control (20 ng) 1 DAUGHTER Vector (20 ng) 1 Electra Buffer (10x) 2 Electra Enzyme (20x) 1 Water 15 Total 20 1. Combine components and incubate at 25-37 C for 5-20 minutes. 2. Transform 1-2 µl into chemically competent E. coli. (DH10B cells recommended) 3. Recover cells for 45 minutes and then plate on appropriate antibiotic for the DAUGHTER. 3a. Optionally include streptomycin at 100 µg/ml (for selection against pmother with rpsl); or plate on YEG with antibiotic plus p-chloro phenylalanine at 10mM (for selection against pmother with phes). Positive Control A positive control MOTHER vector carries a gene in which Ptet drives expression of green fluorescent protein (DasherGFP). A successful Electra reaction will produce green fluorescent colonies from the DAUGHTER vector. Electra DAUGHTER Vectors Electra DAUGHTER vectors are supplied as linearized DNA, with overhangs compatible with an ATG (encoding methionine) at the 5' end and GGT (encoding glycine) at the 3' end.

Electra MOTHER Vectors Genes in MOTHER vectors have adjacent restriction sites that produce overhangs compatible with an ATG at the 5' end and GGT at the 3' end upon digestion with SapI. Alternatively Electra ends can be added to any gene* by PCR. We recommend you add the following ends to your PCR primers: 5'-TACACGTACTTAGTCGCTGAAGCTCTTCTATG...(ORF)...-3' 5'-TAGGTACGAACTCGATTGACGGCTCTTCTACC...(ORF Reverse Complement)...-3' *Your gene must not contain any internal SapI recognition sites, since the Electra cloning process utilizes the typeiis enzyme SapI. MOTHER vectors also contain a counter-selection gene. This can be used to eliminate any residual gene propagating in the MOTHER.

Feature list descriptions Blasticidin-r complementary poly purine tract (cppt) EES Intron_EF1a-Hs Kanamycin-r LTR_HIV 1 LTR_RSV Ori_pUC P_EF1a- Hs,P_EF1a_(min)- Hs P_PGK-Mm pa_hsv TK Pack_HIV 1 Rev-responsive element_hiv 1 WPRE Blasticidin is a peptidyl nucleoside antibiotic that inhibits protein synthesis by interfering with the peptide bond formation in the ribosomal machinery. Resistance to blasticidin is conferred by the blasticidin resistance gene from Bacillus cereus (bsr) which codes for blasticidin S- deaminase. Cell death induced by blasticidin is rapid and cell lines carrying a blasticidin resistance gene can be obtained in less than a week. Typically, mammalian cells are sensitive to blasticidin concentrations of 1-10 µg/ml, and bacteria to 25-100 µg/ml. (www.ncbi.nlm.nih.gov/ pubmed/1720391) A stretch of purine residues, the polypurine tract (PPT) is found in all retroviruses and is used to initiate plus-strand DNA synthesis. The sites of plus-strand and minus-strand initiation are important because they ultimately define the ends of the full-length proviral DNA, which are recognized by the viral integrase. Incorporation of a central polypurine tract (cppt) into lentiviral vectors provides increased transduction efficiency and transgene expression. (www.jvi.asm.org/content/79/11/6859.full) DNA2.0's proprietary expression enhancement element The human elongation factor one alpha (EF1 alpha) first intron comprises enhancer elements and has been shown to enhance expression of heterologous proteins in mammalian cells. (www.ncbi.nlm.nih.gov/pubmed/11738725) An effective bacteriocidal agent that inhibits ribosomal translocation thereby causing miscoding. The gene coding for kanamycin resistance is Neomycin phosphotransferase II (NPT II/Neo). E.coli transformed with plasmid containing the kanamycin resistance gene can grow on media containing 25 µg/ml kanamycin. Kanamycin is a white to off-white powder that is soluble in water (50mg/ml). (www.en.wikipedia.org/wiki/ Kanamycin) Long terminal repeats (LTRs) are identical sequences of DNA that repeat hundreds or thousands of times. They are found at either end of retrotransposons or proviral DNA formed by reverse transcription of retroviral RNA. They are used by viruses to insert their genetic material into the host genomes. The HIV-1 LTR is approximately 640 bp in length and is similar to other retroviral LTRs. The LTRs are partially transcribed into an RNA intermediate, followed by reverse transcription into complementary DNA (cdna) and ultimately dsdna with full LTRs. The LTRs then mediate integration of retroviral DNA via an LTR specific integrase into another region of the host chromosome. (www.jvi.asm.org/ content/74/8/3740) Long terminal repeats (LTRs) are identical sequences of DNA that repeat hundreds or thousands of times. They are found at either end of retrotransposons or proviral DNA formed by reverse transcription of retroviral RNA. They are used by viruses to insert their genetic material into the host genomes. The Rous sarcoma virus (RSV) LTR contains a transcriptionally potent enhancer and promoter that functions in a variety of cell types. (www.pnas.org/content/79/22/6777.full.pdf) The origin of replication is a sequence in a genome at which replication is initiated. The puc ori is a mutated form of origin derived from E. coli plasmid pbr322 which allows production of greater than 500 copies of plasmid per cell. (www.en.wikipedia.org/wiki/origin_of_replication) EF1 a promoter is a constitutive mammalian promoter used to drive ectopic gene expression in various in vitro and in vivo contexts. The EF-1 alpha promoter, which offers a broad host range, is derived from the human EF1A1 gene that expresses the alpha subunit of eukaryotic elongation factor 1. EF-1 alpha promoters allow robust, constitutive, long-term expression of your gene of interest in cell types in which CMV promoters are often silenced, such as hematopoietic and stem cells. The EF1 a promoter is shown to be superior to the CMV promoter in undifferentiated mouse, monkey and human ESCs. (www.plosone.org/article/info%3adoi%2f10.1371%2fjournal.pone.0010611) The mouse phosphoglycerate kinase I promoter (PGK) is a weak constitutive promoter compared to CMV, EF1 alpha and SV40. (www.plosone.org/ article/info%3adoi%2f10.1371%2fjournal.pone.0010611) A polyadenylation signal from the Herpes simplex virus thymidine kinase (HSV-TK) gene that gives efficient transcription termination and polyadenylation of mrna. (www.link.springer.com/article/10.1023/a%3a1007956013403#page-1) The RNA genome of the human immunodeficiency virus type-1 (HIV-1) contains a ~120 nucleotide Ψ-packaging signal that is recognized by the nucleocapsid (NC) domain of the Gag polyprotein during virus assembly. (www.sciencedirect.com/science/article/pii/s0022283600939792) The HIV-1 Rev response element (RRE) is a ~ 350 bp nucleotide, highly structured, cis-acting RNA element essential for viral replication. It was identified in the envelope gene (env) of the viral genome and is extremely well conserved across different HIV-1 isolates. (www.ncbi.nlm.nih.gov/ pubmed/22258145) A cis-acting element, the Woodchuck hepatitis post-transcriptional regulatory element (WPRE), contributes to higher transgene expression. (www.ncbi.nlm.nih.gov/pubmed/17597793) Licenses pd1300, 1400, 2100, 2500, 2600 & Proprietary Mammalian Expression Vectors - RESEARCH USE ONLY Any product containing pd1300, pd1400, pd2100, pd2500, pd2600, pd3500, or pd3600-series Vectors (the Licensed Vectors ) (including Electra vectors, vector configurations for expression of multiple genes and other customized configurations of the Licensed Vectors, and ProteinPaintbox genes or CUSTOMER genes cloned into the Licensed Vectors) is subject to a limited, non-transferable license pursuant to which CUSTOMER acknowledges and agrees that the Licensed Vector may be used for internal research purposes only and may not be used for commercial purposes. For clarity, use for commercial purposes includes any use in manufacturing a product or service that is provided to a third party for consideration. In addition, CUSTOMER acknowledges and agrees that CUSTOMER and any Authorized Transferee (as defined in Section 11) may not (a) modify the Licensed Vectors in any way, including but not limited to replacing any protein-encoding sequence with any other protein-encoding sequence; (b) reverse-engineer, deconstruct, or disassemble the Licensed Vectors; (c) create any variant or derivative vector of the Licensed Vectors; or (d) transfer, disclose, or otherwise provide access to the Licensed Vectors (including sequences of same) to any third party other than an Authorized Transferee, and provided that any transfer to an Authorized Transferee must comply with the Product Transfer terms of Section 11.